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Abstract 
 
There is a large interest in the use of nucleic acids covalently bound to surfaces for a 
variety of biomedical uses; biosensors, microarrays, drug delivery, lab-on-chip devices 
and gene therapy etc. Most of these applications require the covalent attachment of 
oligonucleotides via specific reactive groups on both modified oligonucleotide and/or 
surface. The purpose of this chapter is to provide experimental protocols for the 
synthesis of oligonucleotides and for the immobilization of these synthetic 
oligonucleotides onto surfaces such as gold and silicon oxide.  
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1. Introduction 
The repair and maintenance of living tissues and organs in vivo is a complex task, 
regenerative medicine aims to achieve this goal through an amalgamation of synthetic 
and natural means. The covalent coupling and patterning of biomolecules is expected to 
play an important role in the development of new biomedical devices (1). Grafting of 
oligonucleotides to planar surfaces for high throughput parallel screening of 
biomolecules by ‘lab-on-chip’ devices offers the possibility of rapid diagnosis and 
analysis (2-5). Furthermore short synthetic oligonucleotides can be used to immobilise a 
variety of organic and inorganic materials onto a surface, such modified surfaces may 
be used to study the physicochemical properties that affect cellular function (6-9). Also 
of interest is the development of targeted delivery systems based on nanoparticles or 
liposomes (10,11). A sophisticated delivery system incorporating bioactive molecules 
on a surface could provide multiple complementary therapies in a single dose while also 
sending feedback via reporter molecules (12). 
To fabricate devices requiring the attachment of a biomolecule to a substrate, a specific 
and robust coupling procedure is necessary (13). In this protocol we are focusing on 
oligonucleotide conjugation to surfaces. Oligonucleotides are short nucleic acid 
polymers that can easily be synthesised purified and modified within the confines of 
modern solid phase synthesis. There are two primary substrates identified, gold and 
silicon oxide, however the coupling methods described are transposable to other 
suitable surfaces. Covalent coupling to each substrate requires different modifications to 
the synthetic oligonucleotide. This can be achieved with the use of specialized reagents 
that are compatible to DNA synthesis conditions and that are able to generate the 
appropriate functional groups at specific sites on a synthetic oligonucleotide. For a gold 
surface the modification of choice is the addition of a thiol moiety to the 3’ or 5’ end of 
the oligonucleotide. The strong affinity of a thiol group for gold results in the 
chemisorption of the oligonucleotide followed by oxidation of the gold to form a 
covalent bond (14, 15). When grafting to a silicon oxide substrate there is a greater 
variety of methods to choose from. Of the current methods it has been shown that use of 
an amine layer followed by the coupling with a homobifunctional linker, 1,4 
phenylenediisothiocyanate, followed by grafting of an amine modified oligonucleotide 
provides a useful and robust method for the covalent attachment of oligonucleotides 
(see Note 1) (16-18). 
In this regard we describe protocols to synthesise and couple thiol terminated 
oligonucleotides to gold surfaces and amine terminated oligonucleotides to 
isothiocyanate modified silicon surfaces. 
 
Fig. 1 near here 
 
2. Materials 
2.1 Synthesis of oligonucleotides carrying amino or disulfide groups at the 5’- or 3’-
ends. 
1. Prepare oligonucleotides sequences using solid-phase methodology and 2-cyanoethyl 
phosphoramidites as monomers. The phosphoramidites of the natural nucleosides are 
commercially available (see Note 2).  
2. Ancillary reagents required for oligonucleotide synthesis are: 0.4 M 1H-tetrazol in 
ACN (activation); 3% trichloroacetic acid in DCM (detritylation), acetic anhydride / 
pyridine /tetrahydrofurane (1: 1: 8) (capping A), 10 % N-methylimidazole in 
tetrahydrofurane (capping B), 0.01 M iodine in tetrahydrofurane/ pyridine /water (7: 2: 
1) (oxidation). These solutions can be obtained from the same companies that provide 
phosphoramidites (see Note 2).  
3. Reagent used for the introduction of an amino group at the 3’-end: 3’-amino-modifier 
C7 CPG (see Fig. 1 and Note 2). 
4. Reagent used for the introduction of an amino group at the 5’-end: MMT-amino 
modifier C6 phosphoramidite (see Fig. 1 and Note 2). 
5. Reagent used for the introduction of a disulfide group at the 3’-end: 3’-thiol-modifier 
C3 S-S CPG (see Fig. 1 and Note 2). 
6. Reagent used for the introduction of a disulfide group at the 5’-end: 5’-thiol modifier 
C6 S-S phosphoramidite (see Fig. 1 and Note 2). 
7. HPLC solutions are as follows. Solvent A: 5% acetonitrile in 100 mM 
triethylammonium acetate (pH 6.5) and solvent B: 70% acetonitrile in 100 mM 
triethylammonium acetate pH 6.5.  
8. Rhodamine derivative carrying a maleimido group: Tetramethylrhodamine 5-
maleimide (Fluka). 
 
2.2 Functionalization of gold surfaces with oligonucleotides. 
1. Ultra high purity (UHP) water was purified using a UHQ filtration system and used 
with resistivity > 18 Ω cm-1. 
2. Substrates of gold evaporated on mica (template stripped gold), prepared in house. 
(see Note 3) 
3. 3’ or 5’ Disulfide modified oligonucleotide. (see Note 4) 
4. Solution for the immobilization of disulfide-oligonucleotides: 1.0 M Potassium 
dihydrogen phosphate buffer (KH2PO4). 
5. 6-mercaptohexanol solution: 1mM in UHP water. 
6. Hybridization solution: ~1 nM solution of 10 nm gold nanoparticles conjugated to 
complementary oligonucleotide (18, 19) in 0.01 M phosphate buffer pH 7.0, 0.3 M 
NaCl. 
7. Washing solution to remove salt from surface: ammonium acetate 0.03 M in UHP 
water. 
 
2.3 Functionalization of silicon oxide surfaces with oligonucleotides 
1. UHP water was purified using a UHQ filtration system and used with resistivity > 18 
Ω cm-1. 
2. Silicon wafers (Si/SiO2) were purchased from CrysTec GmbH. and were of the type: 
a) <100> orientation, b) resistance of 1-20 Ω cm-1, c) 200 nm thick oxide layer on both 
sides and d) polished on one side.  
3. Piranha solution: Concentrated sulfuric acid (H2SO4) and 30 % hydrogen peroxide 
(30 % H2O2), (70:30). Caution: Solution dangerously attacks organic matter! 
4. RCA (Radio Corporation of America) solution: UHP water; 30% H2O2; 33% NH4OH 
in a ratio of 5:1:1 respectively. 
5. APTMS solution: 0.5 mM solution of (3-aminopropyl)-trimethoxysilane (APTMS) in 
5 mL of anhydrous ethanol.  
6. PDITC solution: 0.2% solution of 1,4-diphenylenediisothiocyanate (PDITC) in 10% 
pyridine/DMF.  
7. 3’- or 5’-amino modified oligonucleotide. 
8. Solution for the immobilization of amino-oligonucleotides: 10mM oligonucleotide-
NH2 in 1M Tris-HCl (pH 7.0) with 1% N,N-diisopropylethylamine. 
9. Amine passivation solution: 50mM 6-amino-1-hexanol, 150mM N,N- 
diisopropylethylamine in UHP water. 
10. 20x SSC concentrate (Saline Sodium Citrate: 0.3 M sodium citrate, 3.0 M NaCl, pH 
7.0) 
11. Hybridization solution: 20 mM solution of the rhodamine labelled oligonucleotide in 
5 x SSC containing 1% SDS and 20% formamide. 
 
2.4 Functionalization of glass slides with oligonucleotides. 
1. Glass slides functionalized with poly-(Lys) (MENZEL-GLASER, P4981-602677-
CE). 
2. PDITC solution: 0.2% (w/v) solution of 1,4-phenylene diisothiocyanate (PDITC) in 
10% pyridine / dimethylformamide. 
3. Solution used for the immobilization of amino-oligonucleotides: 10 mM 
oligonucleotide in 0.1 M Borate-Na buffer, pH 8.0. 
4. Passivation solution: 1 g of succinic anhydride in 50 mL of N-methylpyrrolidinone 
and 5.6 mL 0.2 M Borate-Na buffer, pH 8.0. 
5. Prehybridization solution: a solution of 1% bovine serum albumin (BSA), in 6x SSC 
(saline sodium citrate, see 2.3.10).  
6. Hybridization solution: 20 mM solution of the rhodamine labeled oligonucleotide in 5 
x SSC containing 1% SDS and 20% formamide. 
 
3. Methods 
As discussed, there is a large interest in the use of biomolecules covalently bound to 
surfaces for a variety of biomedical applications. Covalent attachment of 
oligonucleotides to surfaces requires modification of the oligonucleotides and often 
modification of the surface utilised. There are a large number of protocols to immobilize 
oligonucleotides to surfaces (3-5, 13). In this work we describe robust methods for the 
immobilization of synthetic oligonucleotides onto gold, glass and silicon oxide surfaces. 
As recent examples of the potential applications developed from our group using the 
methodologies described here we underline the formation of patterns on silicon oxide 
substrates using hairpin oligonucleotides carrying photolabile groups (18) and the use of 
thiolated oligonucleotides to form 2D-DNA arrays on gold surfaces (15). 
 
Fig. 2 near here 
 
3.1 Synthesis of modified oligonucleotides 
1. Prepare oligonucleotide sequences were prepared using solid-phase methodology and 
2-cyanoethyl phosphoramidites as monomers. Synthesize were performed on a DNA 
synthesizer using either 0.2 or1 mmol scales. 
2. The solid supports used more frequently for the introduction of amino or thiol groups 
at the 3’-ends are shown in Fig. 1. For the introduction of an amino group use the 3’-
amino-modifier C7 CPG. This support is a controled pore glass (CPG) support 
functionalized with an amino-diol, having the amino group protected with the 9-
fluorenylmethyloxycarbonyl (Fmoc) group (see Note 5) (20). For the introduction of the 
thiol or disulfide group use the 3’-thiol-modifier C3 S-S CPG. This support is a CPG 
support functionalized with the hydroxypropyldisulfide protected with the 
dimethoxytrityl (DMT) group. 
3. The introduction of amino or disulfide groups at the 5’-end needs the use of a special 
phosphoramidite (Fig. 1). For the introduction of an amino group at the 5’-end use the 
MMT-amino modifier C6 phosphoramidite (21). This reagent is a derivative of 6-
aminohexanol with the monomethoxy (MMT) group for the protection of the amino 
group (see Note 6). For the introduction of a thiol or disulfide group at the 5’-end use 
the 5’-thiol modifier C6 S-S phosphoramidite.  
4. After the assembly of sequences, deprotect in 30% aqueous ammonia solution 
overnight at 55 ºC. If oligonucleotides carrying a free thiol group are required deprotect 
with 1 mL of 0.1 M dithiothreitol (DTT) in 30% aqueous ammonia solution (see Note 
4). 
Purify oligonucleotides carrying amino groups by reverse-phase HPLC. HPLC solutions 
are described above (Subheading 2.1). Columns: Nucleosil 120C18 (10 mm), 200 x 10 
mm. Flow rate: 3 mL/min. Conditions A: 20 minutes linear gradient from 15-80% 
(DMT on). Conditions B: 20 minutes linear gradient from 0-50% B (DMT off). The 
DMT or MMT-oligonucleotides are purified using conditions A (22). The major peak 
containing the DMT- or MMT-oligonucleotide will elute around 10-12 minutes. 
6. Collect the eluates and concentrate to dryness and treat the residue with 80% acetic 
acid in water. After 30 min, add 1 mL of water and extract the acetic acid with ethyl 
ether (3 times). Repurify the resulting aqueous solution by HPLC using conditions B.  
7. Purify oligonucleotides carrying free thiol groups and DTT in a NAP-5 or NAP-10 
(Sephadex G25) column elute with water according to the manufacturer’s protocol.  
Deptrotected oligonucleotides with a free thiol should be used immediately without 
further purification.  
8. The synthesis of rhodamine-labelled complementary oligonucleotide is performed by 
reaction of a free thiol-oligonucleotide with tetramethylrhodamine 5-maleimide (see 
Note 7). Add a large excess of maleimido-rhodamine (1mg) to the NAP purified 
deprotected thiol-oligonucleotide (0.5 mL) and allow shake gently for 4 hours at room 
temperature. Concentrate the solution to dryness and then redissolve in 0.5mL water. 
Purify in a NAP-5 (Sephadex G-25) column eluting with water to separate the desired 
conjugate from the excess maleimido rhodamine. Purify the conjugate further by HPLC 
using conditions A (DMT on). The product carrying the fluorescent oligonucleotide 
(retention time 8 min) is isolated in ~70% yield. 
 
Fig. 3 near here 
 
3.2 Immobilization of oligonucleotides on gold substrates 
1. Depending on gold substrate chosen cleave gold substrate from support or clean 
according to suppliers guidelines (see Note 3). 
2. Drop cast 10 mL a 3mM solution of the disulfide oligonucleotide in immobilisation 
buffer onto the gold surface. Ensuring the drop covers the required area. 
3. Incubate the substrate in a humid environment for 10 hours. Following incubation 
wash with UHP water to remove any non-covalently bound oligonucleotides. 
4. Drop cast 15 mL of 1 mM 6-mercaptohexanol onto the gold surface. Incubate in a 
humid environment for 1 hour. Wash the solution with UHP water. Mercaptohexanol 
passivates the gold surfaces and improves hybridisation efficiency. 
5. The conjugated oligonucleotide can then be hybridised with a nanoparticle label. 
Drop cast a solution of 10 nm gold particles carrying a complementary oligonucleotide 
on the gold surface for 2 hours in a humid environment at room temperature. Wash 
three times 0.3 M NaCl, 0.01 M phosphate buffer, pH 7 and once with 0.03 M 
ammonium acetate. 
 
Fig. 4 near here  
 
3.3 Functionalization of self-assembled monolayers (SAM) on silicon oxide surfaces 
1. Cut silicon wafers into squares of approximately 1 cm x 1 cm using a diamond tipped 
scriber. Rinse the substrates with ethanol to remove of any dust that was produced 
during the cutting process.  
2. Immerse the cut silicon in piranha solution at 90-100 °C for 60 minutes. Once cooled, 
rinse off the piranha solution with UHP water.  
3. Agitate in an ultrasonic bath in RCA solution for 60 minutes. Sonication in RCA at 
this stage functionalises the surface with hydroxyl groups to allow monolayer 
formation. Rinse the substrates in UHP water to finish the cleaning procedure. The 
substrates are then stored in UHP water and used within 2 days to minimise loss of 
surface hydroxyl groups. 
4. Transfer the cleaned silica substrates from UHP water to anhydrous ethanol by 
stepwise exchange (H2O:EtOH)- 3:1 , 2:2 , 1:3 , 0:4 and finally anhydrous ethanol. In a 
nitrogen atmosphere immerse the substrates in APTMS solution and sonicate at room 
temperature for 1 hour. Rinse the substrates for 20 seconds each with ethanol and 
chloroform. Sonicate the wafers twice in fresh ethanol for 5 minutes followed by a final 
sequential rinsing with ethanol and chloroform. Dry samples under a steady stream of 
nitrogen and cure at 120 °C for 30 minutes under vacuum to promote cross-linking of 
the SAM’s. 
5. Incubate APTMS functionalised silicon wafers for 2 hours in PDITC solution. After 
incubation, wash with methanol and acetone and stored in vacuum desiccators. 
6. Deposit a drop of oligonucleotide-NH2 solution onto substrate and incubate at 37 °C 
for 2 hours. Wash samples with 1% ammonium hydroxide and copious amounts of UHP 
water. Immerse wafers in amine passivation solution for 2 hours. Dry under a steady 
stream of N2 and store under vacuum in a desiccator. 
7. Drop cast fluorescently labelled complementary in hybridisation buffer on the wafer. 
Incubate for 2 hours at room temperature. Wash with 5x SSC and finally with 1x SSC.   
 
Fig. 5 near here 
 
3.3 Immobilization of oligonucleotides on glass substrates 
1. Clean amine functionalised glass slides 10 times with acetone and dry for 45 minutes 
at 90 ºC.  
2. Treat glass slides with PDITC solution for 2 hours at room temperature. Wash glass 
slides with methanol (3x) and acetone (2x). Use glass slides immediately. 
3. Add the desired amount of amino-oligonucleotide immobilization solution to the 
glass slide. Incubate for 2 hours at 37 ºC and then wash with 1% NH4OH and water (30 
mL x 5). 
4. Agitate in succinic anhydride passivating solution for 2 hours. This post-processing is 
required to passivate the charged surface. Rinse by agitating in UHP water and ethanol 
96%, centrifuge for 6 min at 1500 r.p.m. and dry with a steady stream of argon. 
5. Prehybridize with the bovine serum albumin solution for 10 minutes at room 
temperature. Drop cast the hybridization solution to the requires area and incubate in a 
humid environment for 2 hours at room temperature. Measure the fluorescence profile 
on a fluorescence scanner. 
 
4. Notes 
1. Outside the scope of this short procedure is the electrostatic binding of DNA to 
surfaces and also the use of different types of substrates. The type of surface chosen is 
dependent on the required use and the type of characterisation envisaged. Described 
here is the fabrication of very flat amine monolayers on high grade silicon wafers; this 
method facilitates characterisation by AFM. Using prefabricated amine terminated glass 
slides may be sufficient if one is only using fluorescent microscopy as detection 
method.  
2. There are several companies that provide regular phosphoramidite, ancillary reagents 
and solid supports for oligonucleotide synthesis such as Applied Biosystems and Sigma. 
In addition to standard reagents, more elaborate phosphoramidites and solid supports 
can be found at companies specializing in oligonucleotide reagents such as Link 
technologies (Scotland), Glen Research (Sterling, VI, USA), Berry & Associates 
(Dexter, MI, USA), TriLink Biotechnologies (San Diego, CA, USA), Nedken (Foster 
City, CA, USA), ChemGenes (Wilmington, MA, USA), Prime Synthesis (Aston, PA, 
USA) and Metkinen (Finland).  
3. There are many suitable gold substrates commercially available. Suitability of one 
substrate over another depends on application. Some suppliers include Arandee 
(Wether, Germany), Asylum Research (Santa Barbara, CA, USA) and Sigma Aldrich. 
Some require cleaning steps to remove organic and inorganic build-up, such cleaning 
procedures are usually supplied by the manufacturer. During our research we have used 
gold coated mica substrates prepared in house using a method first described by Hegner 
et al. (23), which have the advantage of not requiring a cleaning step and can be used 
‘as is’ when cleaved from a support. 
4. It is worth discussing the use of disufide and thiol modified oligonucleotides. 
Disulfide oligonucleotides such as those in Fig. 2 have the advantage that they are 
stable to long-term storage and spontaneously react with gold surfaces. Alkylthiol-
protected thiol strands normally bear disulfide protecting groups that must be removed 
before conjugation. This is done by adding a cleavage agent such as DTT or DTE which 
cleaves the disulfide bond; however DTT or DTE needs to be removed from the free 
thiol for it to react with a gold surface or any other suitable reactive group. This is done 
by size exclusion gravity chromatography (NAP-5 and NAP-10 columns). Often if a 
thiol oligonucleotide is purchased from a commercial supplier it will contain DTT or 
DTE. 
5. During the addition of the MMT-amino-modifier C6 it is important to avoid the 
capping reaction because the MMT-amino group can be acetylated giving an unreactive 
acetyl derivative of the oligonucleotide (24, 25). Moreover, some authors described low 
efficiency of the removal of the MMT group. To solve this problem new amino linkers 
have been described (26) but they are not commercially available. Alternatively the 
trifluoroacetyl (TFA) derivative of 6.aminohexanol (5’-TFA-amino modifier C6 
phosphoramidite) can be used. The TFA group is removed during the ammonia so 
HPLC purification based on the presence of the MMT group is not possible. 
6. Some authors have described that the Fmoc group protecting the amino function is 
partially lost during the synthetic process and becomes acetylated during capping 
conditions (27). In shorter sequences we have also found a side product (5-10%) with a 
molecular weight 100 units higher than expected. We assign this side product to a 
succinylated amino oligonucleotide. This side compound can be produced by internal 
aminolysis of the succinyl ester. The use of a commercially available phthaloyl linker 
(3’-PT-amino modifierC6 CPG) is a good alternative to increase the yield of final 
product (27).  
7. In addition to the conjugation with fluorescent derivatives carrying maleimido groups 
there are several phosphoramidites and solid supports that can be found at companies 
specializing in oligonucleotide reagents that allow the rapid preparation of 
fluorescently-labelled oligonucleotides.  
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 Fig. 1. Phosphoramidites and solid supports used in the preparation of oligonucleotides 
carrying amino or thiol groups at their 3’- or 5’-ends.  
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 Fig. 2. Reaction of a thiol-oligonucleotide with tetramethylrhodamine 5-maleimide to 
yield a rhodamine labelled oligonucleotide. 
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 Fig. 3. Scheme of the grafting of an oligonucleotide to a silicon wafer. Wafers are 
incubated with a solution of APTMS (step 1) followed by crosslinking (step 2) to form 
an amine terminated monolayer. Reaction with PDITC (step 3) yields a thiocyante 
terminated layer which in turn can be reacted with an amine functionalised 
oligonucleotde (step 4). Hybridisation with a labelled complementary oligonucleotide 
demonstrates the successful grafting of the amine oligonucleotide to the surface. 
 
 
 
 
 
  
 
Fig. 4. AFM image of a gold substrate functionalized with an oligonucleotide and 
hybridized with complementary oligonucleotide labelled with 10 nm gold nanoparticles. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig. 5. Fluorescent image of a silicon oxide substrate functionalized with an 
oligonucleotide (right) and hybridized with complementary oligonucleotide labelled 
with Rhodamine (left). Inset in the right side shows the AFM image of the silicon 
surface functionalized with double stranded oligonucleotides (after hybridization).  
 
 
